Results 201 to 210 of about 29,889 (292)

Theorizing causality: A qualitative study of xylazine‐related wound diversity and perceived etiology among people who inject drugs

Addiction, Volume 121, Issue 7, Page 1794-1807, July 2026.
Abstract Background and aims Incidence and severity of opioid‐associated skin and soft‐tissue infections, often requiring intensive and costly medical care, have increased substantially since the emergence of xylazine in the US drug supply. Although progress has been made in clinical and harm reduction recommendations for treating xylazine‐related ...
Danielle German, Kelci Villarroel, Meredith Denney, Adrian Guta, Julie Evans, Jason Bienert, Alex Fidler, Kim Ashburn, Zach Kosinski, Becky L. Genberg   +9 more
wiley   +1 more source

Prehospital whole blood transfusion in hemorrhagic shock: A systematic review. [PDF]

Transfusion
Dion PM, Greene A, Aves T, Pan A, Drennan I, von Vopelius-Feldt J, Beckett A, Shorr R, Nolan B.   +8 more
europepmc   +1 more source

Supporting Children With a Chronic Disease and Their Parents When Admitted to Hospital: A Scoping Review of Psychosocial Supports

Acta Paediatrica, Volume 115, Issue 7, Page 1322-1372, July 2026.
Importance of psychosocial support. ABSTRACT Aim The aim of this scoping review was to identify, examine, and summarize available evidence regarding psychosocial supports provided to children with a chronic disease when admitted to hospital and their parents. Method The JBI methodology for conducting and reporting scoping reviews was followed.
Lyndsay Jerusha MacKay, Nolan Lagrisolal, Una Chang, Matthew Christoffersen, K. Alix Hayden, Kathryn Birnie, Tammie Dewan   +6 more
wiley   +1 more source

Incidence and sex-related risk factors of linezolid-associated adverse drug reactions identified through electronic health records. [PDF]

Transl Clin Pharmacol
Baek S, Oh J, Yoon S, Yoon S, Chung JY.
europepmc   +1 more source

Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 2, Page 166-176, July 2026.
Hepcidin levels predict response to iron therapy and support route selection for iron therapy in patients with active inflammatory bowel disease: higher levels favour IV iron, while lower levels indicate likely oral response. Ferritin‐based indices, particularly transferrin/log10(ferritin) and sTfR/log10(ferritin), offer reliable alternatives. ABSTRACT
Lola J. M. Koppelman, Roberta Loveikyte, Rogier L. Goetgebuer, Sander van der Marel, Annemarie C. de Vries, Gerard Dijkstra, Andrea E. van der Meulen‐de Jong, on behalf of the Dutch Iron Study Group, M. Duijvestein, M. van der Have, C. Horjus, W. G. N. Mares, Z. Mujagic, B. Oldenburg, R. West   +14 more
wiley   +1 more source

Transfusion Reactions in Paediatric Patients; Hemovigilance Data from a Tertiary Hospital. [PDF]

Children (Basel)
Durak F, Tezol Ö.
europepmc   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, Volume 117, Issue 1, Page 144-153, July 2026.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

A Clinical Investigation of Hypoxic Red Blood Cell Administration in Patients with Transfusion-Dependent Hematological Malignancies and Burns. [PDF]

J Blood Med
Reikvam H, Lunde THF, Kristoffersen EK, Omert L, Bagdasarian J, Almeland SK.   +5 more
europepmc   +1 more source

Circulating CAR T‐Cells After Treatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Aggressive B‐Cell Lymphomas and Its Association to Treatment Outcome

European Journal of Haematology, Volume 117, Issue 1, Page 227-234, July 2026.
ABSTRACT Objectives This study investigates the expansion of CAR T‐cells and its association to treatment outcome. Methods Patients with aggressive B‐cell lymphomas treated with anti‐CD19 CAR T‐cell therapy axicabtagene ciloleucel (axi‐cel) at Skåne and Sahlgrenska University Hospitals from 2019 to October 2024 were included.
Louise Olsson Werne, Evelina Elmér, Mikael Lisak, Róbert Pálmason, Annika K. Hult, Josefina Dykes, Mats Jerkeman   +6 more
wiley   +1 more source

Blood Transfusion Practices in Rural Hospitals: Indications, Challenges, and Practical Solutions. [PDF]

Cureus
Topno VR, Bihari G, Mishra G, Kumar D.
europepmc   +1 more source